கரோலினாஸ் வலி நிறுவனம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from கரோலினாஸ் வலி நிறுவனம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In கரோலினாஸ் வலி நிறுவனம் Today - Breaking & Trending Today

First Patient Treated in Landmark U.S. Randomized Clinical Trial of NeuraLace's Chronic Pain Treatment


Share this article
Share this article
SAN DIEGO, May 27, 2021 /PRNewswire/  NeuraLace Medical, Inc., a medical device company focused on improving pain relief among patients suffering from debilitating chronic nerve pain, announced today that the first patient has been enrolled as part of the AXON-RCT U.S. study: a prospective, randomized, controlled clinical trial comparing the safety and effectiveness of Axon Therapy® for post-traumatic peripheral neuropathic pain to conventional medical management.  The Primary Investigator of the study will be Dr. Leonardo Kapural of the Carolinas Pain Institute.
We are incredibly excited to start our Axon-RCT study with Dr. Kapural s team to begin testing Axon Therapy on patients that suffer from chronic peripheral nerve pain,  said Shiv Shukla, Founder and CEO of NeuraLace Medical. ....

Winston Salem , North Carolina , United States , University Of Kansas Medical Center , San Diego , Kansas City , Dawood Sayed , Leonardo Kapural , Carolinas Pain Institute , Neuralace Medical Inc , Neuralace Medical , Axon Therapy , Primary Investigator , Carolinas Pain , Shiv Shukla , Kansas Medical Center , Conventional Medical Management , வின்ஸ்டன் ஸேலம் , வடக்கு கரோலினா , ஒன்றுபட்டது மாநிலங்களில் , பல்கலைக்கழகம் ஆஃப் கன்சாஸ் மருத்துவ மையம் , சான் டியாகோ , கன்சாஸ் நகரம் , தாவூத் என்றார் , கரோலினாஸ் வலி நிறுவனம் , ஆக்சன் சிகிச்சை ,

Nevro to Highlight New Clinical Evidence at the 2021 North American Neuromodulation Society (NANS) Virtual Meeting


Nevro is proud to continue our longstanding commitment to investing in the field of neuromodulation and expanding our growing body of clinical evidence, said D. Keith Grossman, Chairman, CEO and President of Nevro. We are excited for Dr. Petersen and Dr. Kapural to share the significant data from the SENZA-PDN and the SENZA-NSRBP trials at NANS, reflecting our commitment to helping physicians treat underserved patient populations suffering from debilitating chronic pain. Additionally, we are pleased the many clinical investigators studying HF10 will have the opportunity to present the results of numerous additional studies we are conducting globally.
Key amongst these presentations will be data for the SENZA-Painful Diabetic Neuropathy (PDN) randomized clinical trial (RCT) and a first look at results from the Non-Surgical Refractory Back Pain (NSRBP) RCT: ....

United States , Redwood City , Erika Petersen , Julie Dewey , D Keith Grossman , Leonardo Kapural , Exchange Commission , American Neuromodulation Society , Nevro Corp , Prnewswire Nevro Corp , Carolinas Pain Institute , Investor Relations Corp Communications , University Of Arkansas , Virtual Meeting , Painful Diabetic Neuropathy , Non Surgical Refractory Back Pain , Diabetic Neuropathy , Restorative Neurosurgery , Medical Sciences , Principal Investigator , Central Time , Breaking Abstract Plenary Session , Surgical Refractory Back Pain , Medical Director , Host Investor Briefing , Chief Medical Officer ,